![](https://www.biopharmadive.com/imgproxy/8xA0k2HGhsEz9A6Y64VM3yoGUmKZE4twVX3PMGTttkw/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTIxNTgzMDUyOTEuanBn.webp)
Novo nixes trial of blood pressure drug it bought in deal worth $1.3B
Dive Brief: Novo Nordisk will end a Phase 3 clinical trial of a hypertension drug it bought for up to
Read MoreJuly 2, 2024
Dive Brief: Novo Nordisk will end a Phase 3 clinical trial of a hypertension drug it bought for up to
Read MoreOzempic and GLP-1 drugs like it became household names due to their potent weight loss benefits, and are now proving
Read MoreDive Brief: Wave Life Sciences on Tuesday said it will meet with regulators to discuss what kind of evidence would
Read MoreDive Brief: Novo Nordisk will spend $4.1 billion to build a new U.S. factory in North Carolina, the latest multibillion-dollar
Read MoreDive Brief: Novo Nordisk on Sunday disclosed detailed clinical trial results for an experimental hemophilia treatment dubbed Mim8, showing once-weekly
Read MoreToday, a brief rundown of news from Altimmune, Jiangsu Hengrui, Eli Lilly and others that you might have missed from over
Read MoreDive Brief: Amazon has expanded its generic drug savings program to Prime members on Medicare, throwing open the program’s doors
Read MoreDive Brief: Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage
Read MoreAn experimental weight loss shot developed by Denmark-based Zealand Pharma helped people with obesity lose as much as 9% of
Read MoreToday, a brief rundown of news from Jazz Pharma, Vanda Pharmaceuticals, ITM, Ashibio and Novartis that you might have missed
Read More